180 Wealth Advisors LLC Grows Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

180 Wealth Advisors LLC boosted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 23.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,757 shares of the company’s stock after purchasing an additional 5,294 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Elanco Animal Health were worth $406,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Captrust Financial Advisors raised its stake in shares of Elanco Animal Health by 57.0% in the first quarter. Captrust Financial Advisors now owns 2,690 shares of the company’s stock valued at $70,000 after acquiring an additional 977 shares during the period. Covestor Ltd grew its holdings in shares of Elanco Animal Health by 1,285.1% in the first quarter. Covestor Ltd now owns 2,978 shares of the company’s stock worth $78,000 after purchasing an additional 2,763 shares during the last quarter. Comerica Bank bought a new position in shares of Elanco Animal Health in the third quarter worth about $40,000. Advisory Services Network LLC grew its holdings in shares of Elanco Animal Health by 104.1% in the first quarter. Advisory Services Network LLC now owns 5,204 shares of the company’s stock worth $49,000 after purchasing an additional 2,654 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new position in shares of Elanco Animal Health in the fourth quarter worth about $70,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ELAN. Jefferies Financial Group began coverage on shares of Elanco Animal Health in a report on Tuesday, December 19th. They issued a “buy” rating and a $17.00 price target on the stock. The Goldman Sachs Group upped their price target on shares of Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a report on Tuesday, February 27th. Barclays increased their target price on shares of Elanco Animal Health from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Tuesday, February 27th. TheStreet upgraded shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a report on Friday, February 23rd. Finally, Morgan Stanley increased their target price on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $16.71.

Insiders Place Their Bets

In other Elanco Animal Health news, Director R David Hoover purchased 20,000 shares of Elanco Animal Health stock in a transaction on Wednesday, March 6th. The stock was bought at an average cost of $16.14 per share, with a total value of $322,800.00. Following the transaction, the director now owns 185,000 shares of the company’s stock, valued at approximately $2,985,900. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.64% of the stock is currently owned by insiders.

Elanco Animal Health Price Performance

Shares of Elanco Animal Health stock opened at $15.56 on Monday. The company has a quick ratio of 1.35, a current ratio of 2.75 and a debt-to-equity ratio of 0.92. The company has a 50 day moving average price of $15.90 and a 200 day moving average price of $13.48. Elanco Animal Health Incorporated has a 52 week low of $7.88 and a 52 week high of $16.88.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.02). The company had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1 billion. Elanco Animal Health had a negative net margin of 27.87% and a positive return on equity of 6.44%. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.19 earnings per share. As a group, equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.